No connection

Search Results

HCWB vs PRFX

HCWB
HCW Biologics Inc.
BEARISH
Price
$0.36
Market Cap
$2.5M
Sector
Healthcare
AI Confidence
98%
PRFX
PRF Technologies Ltd.
BEARISH
Price
$2.73
Market Cap
$2.3M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
HCWB
--
PRFX
--
Forward P/E
HCWB
-0.66
PRFX
-0.23
P/B Ratio
HCWB
-0.45
PRFX
0.27
P/S Ratio
HCWB
45.26
PRFX
135.62
EV/EBITDA
HCWB
-0.58
PRFX
0.25

Profitability

Gross Margin
HCWB
20.0%
PRFX
0.0%
Operating Margin
HCWB
-18370.3%
PRFX
-16200.0%
Profit Margin
HCWB
0.0%
PRFX
0.0%
ROE
HCWB
--
PRFX
-90.37%
ROA
HCWB
-31.19%
PRFX
-38.75%

Growth

Revenue Growth
HCWB
-93.2%
PRFX
--
Earnings Growth
HCWB
--
PRFX
--

Financial Health

Debt/Equity
HCWB
2.46
PRFX
0.0
Current Ratio
HCWB
0.11
PRFX
1.78
Quick Ratio
HCWB
0.09
PRFX
1.75

Dividends

Dividend Yield
HCWB
--
PRFX
--
Payout Ratio
HCWB
0.0%
PRFX
0.0%

AI Verdict

HCWB BEARISH

HCWB exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is facing a liquidity crisis with a Current Ratio of 0.11 and a catastrophic revenue collapse of -93.20% YoY. With a negative Price-to-Book ratio (-0.45) and an operating margin of -18370.31%, the firm is effectively eroding its remaining capital. The stock's 96% decline over the past year reflects a market pricing in a high probability of insolvency.

Strengths
Positive Gross Margin (20%)
Single analyst target price ($2.00) suggests theoretical upside
Recent 1-week short-term price bounce (+36%)
Risks
Extreme liquidity risk (Current Ratio 0.11)
Catastrophic revenue decline (-93.20% YoY)
Negative shareholder equity (Price/Book -0.45)
PRFX BEARISH

PRFX exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9, which barely places it in the 'stable' category despite catastrophic operating margins of -16,200%. The absence of an Altman Z-Score and Graham Number reflects a lack of positive earnings and stable valuation foundations. With a Price-to-Sales ratio of 135.62 and a 5-year price collapse of 99.7%, the company appears to be a speculative shell with virtually no meaningful revenue generation. While the current ratio of 1.78 provides a temporary liquidity cushion, the fundamental business model is currently non-viable.

Strengths
Zero debt-to-equity ratio
Current ratio of 1.78 indicates short-term liquidity
Recent Q/Q EPS growth showing improvement from deep negatives
Risks
Extreme operating margin of -16,200% indicating massive inefficiency
Absurdly high Price-to-Sales ratio (135.62) suggesting negligible revenue
Total collapse of long-term shareholder value (-99.7% over 5 years)

Compare Another Pair

HCWB vs PRFX: Head-to-Head Comparison

This page compares HCW Biologics Inc. (HCWB) and PRF Technologies Ltd. (PRFX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile